SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue
A novel compound, SB-272183 (5-Chloro-2, 3-dihydro-6-[4-methylpiperazin-1-yl]-1[4-pyridin-4-yl]napth-1-ylaminocarbonyl]-1H-indole), has been shown to have high affinity for human 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors with pK(i) values of 8.0, 8.1 and 8.7 respectively and is at least 30 fold selective over a range of other receptors. [(35)S]-GTPgammaS binding studies showed that SB-272183 acts as a partial agonist at human recombinant 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors with intrinsic activities of 0.4, 0.4 and 0.8 respectively, compared to 5-HT. SB-272183 inhibited 5-HT-induced stimulation of [(35)S]-GTPgammaS binding at human 5-HT(1A) and 5-HT(1B) receptors to give pA(2) values of 8.2 and 8.5 respectively. However, from [(35)S]-GTPgammaS autoradiographic studies in rat and human dorsal raphe nucleus, SB-272183 did not display intrinsic activity up to 10 microM but did block 5-HT-induced stimulation of [(35)S]-GTPgammaS binding. From electrophysiological studies in rat raphe slices in vitro, SB-272183 did not effect cell firing rate up to 1 microM but was able to attenuate (+)8-OH-DPAT-induced inhibition of cell firing to give an apparent pK(b) of 7.1. SB-272183 potentiated electrically-stimulated [(3)H]-5-HT release from rat and guinea-pig cortical slices at 100 and 1000 nM, similar to results previously obtained with the 5-HT(1B) and 5-HT(1D) receptor antagonist, GR127935. Fast cyclic voltammetry studies in rat dorsal raphe nucleus showed that SB-272183 could block sumatriptan-induced inhibition of 5-HT efflux, with an apparent pK(b) of 7.2, but did not effect basal efflux up to 1 microM. These studies show that, in vitro, SB-272183 acts as an antagonist at native tissue 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2001 |
|---|---|
| Erschienen: |
2001 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
British journal of pharmacology - 133(2001), 6 vom: 26. Juli, Seite 797-806 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Watson, J [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 06.09.2001 Date Revised 10.05.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM113569475 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM113569475 | ||
| 003 | DE-627 | ||
| 005 | 20240510231817.0 | ||
| 007 | tu | ||
| 008 | 231222s2001 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1403.xml |
| 035 | |a (DE-627)NLM113569475 | ||
| 035 | |a (NLM)11454652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Watson, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue |
| 264 | 1 | |c 2001 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2001 | ||
| 500 | |a Date Revised 10.05.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a A novel compound, SB-272183 (5-Chloro-2, 3-dihydro-6-[4-methylpiperazin-1-yl]-1[4-pyridin-4-yl]napth-1-ylaminocarbonyl]-1H-indole), has been shown to have high affinity for human 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors with pK(i) values of 8.0, 8.1 and 8.7 respectively and is at least 30 fold selective over a range of other receptors. [(35)S]-GTPgammaS binding studies showed that SB-272183 acts as a partial agonist at human recombinant 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors with intrinsic activities of 0.4, 0.4 and 0.8 respectively, compared to 5-HT. SB-272183 inhibited 5-HT-induced stimulation of [(35)S]-GTPgammaS binding at human 5-HT(1A) and 5-HT(1B) receptors to give pA(2) values of 8.2 and 8.5 respectively. However, from [(35)S]-GTPgammaS autoradiographic studies in rat and human dorsal raphe nucleus, SB-272183 did not display intrinsic activity up to 10 microM but did block 5-HT-induced stimulation of [(35)S]-GTPgammaS binding. From electrophysiological studies in rat raphe slices in vitro, SB-272183 did not effect cell firing rate up to 1 microM but was able to attenuate (+)8-OH-DPAT-induced inhibition of cell firing to give an apparent pK(b) of 7.1. SB-272183 potentiated electrically-stimulated [(3)H]-5-HT release from rat and guinea-pig cortical slices at 100 and 1000 nM, similar to results previously obtained with the 5-HT(1B) and 5-HT(1D) receptor antagonist, GR127935. Fast cyclic voltammetry studies in rat dorsal raphe nucleus showed that SB-272183 could block sumatriptan-induced inhibition of 5-HT efflux, with an apparent pK(b) of 7.2, but did not effect basal efflux up to 1 microM. These studies show that, in vitro, SB-272183 acts as an antagonist at native tissue 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a 5-chloro-2,3-dihydro-6-(4-methylpiperazin-1-yl)-1-(4-(pyridin-4-yl)naphth-1-ylaminocarbonyl)-1H-indole |2 NLM | |
| 650 | 7 | |a HTR1B protein, human |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Receptor, Serotonin, 5-HT1B |2 NLM | |
| 650 | 7 | |a Receptor, Serotonin, 5-HT1D |2 NLM | |
| 650 | 7 | |a Receptors, Serotonin |2 NLM | |
| 650 | 7 | |a Receptors, Serotonin, 5-HT1 |2 NLM | |
| 650 | 7 | |a Serotonin Antagonists |2 NLM | |
| 650 | 7 | |a Serotonin Receptor Agonists |2 NLM | |
| 650 | 7 | |a Sulfur Radioisotopes |2 NLM | |
| 650 | 7 | |a Tritium |2 NLM | |
| 650 | 7 | |a 10028-17-8 |2 NLM | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 650 | 7 | |a Guanosine 5'-O-(3-Thiotriphosphate) |2 NLM | |
| 650 | 7 | |a 37589-80-3 |2 NLM | |
| 650 | 7 | |a N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide |2 NLM | |
| 650 | 7 | |a 71IH826FEG |2 NLM | |
| 650 | 7 | |a 8-Hydroxy-2-(di-n-propylamino)tetralin |2 NLM | |
| 650 | 7 | |a 78950-78-4 |2 NLM | |
| 700 | 1 | |a Roberts, C |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, C |e verfasserin |4 aut | |
| 700 | 1 | |a Kendall, I |e verfasserin |4 aut | |
| 700 | 1 | |a Collin, L |e verfasserin |4 aut | |
| 700 | 1 | |a Day, N C |e verfasserin |4 aut | |
| 700 | 1 | |a Harries, M H |e verfasserin |4 aut | |
| 700 | 1 | |a Soffin, E |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, C H |e verfasserin |4 aut | |
| 700 | 1 | |a Randall, A D |e verfasserin |4 aut | |
| 700 | 1 | |a Heightman, T |e verfasserin |4 aut | |
| 700 | 1 | |a Gaster, L |e verfasserin |4 aut | |
| 700 | 1 | |a Wyman, P |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, C |e verfasserin |4 aut | |
| 700 | 1 | |a Price, G W |e verfasserin |4 aut | |
| 700 | 1 | |a Middlemiss, D N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d 1968 |g 133(2001), 6 vom: 26. Juli, Seite 797-806 |w (DE-627)NLM000001325 |x 1476-5381 |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2001 |g number:6 |g day:26 |g month:07 |g pages:797-806 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 133 |j 2001 |e 6 |b 26 |c 07 |h 797-806 | ||